PsiThera to Participate in Piper Sandler Virtual Novel Targets in Immunology Symposium

WATERTOWN, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- PsiThera, Inc. today announced that Chief Executive Officer Eric Shaff, Founder and Chief Innovation Officer Woody Sherman, Ph.D., and Chief Scientific Officer Camil Sayegh, Ph.D., will participate in a fireside chat at the Piper Sandler Virtual Novel Targets in Immunology Symposium being held on Friday, February 13, 2026, from 9:00 AM to 9:25 AM ET.

About PsiThera
PsiThera is a biotechnology company harnessing biologically relevant protein states and computational intelligence to create oral drugs for immune and inflammatory diseases—therapeutic areas historically reliant on injectables. By integrating biophysics, computational modeling, and mechanistic biology, PsiThera’s expert drug hunters discover new therapeutic opportunities and optimized drugs. The company’s pipeline focuses on high-value targets, starting with the Tumor Necrosis Factor (TNF) superfamily. For more information, visit www.psithera.com or follow us on LinkedIn.

PsiThera Media Contact:
Adam Silverstein - Adam@scientpr.com


Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  198.79
-0.81 (-0.41%)
AAPL  255.78
-5.95 (-2.27%)
AMD  207.32
+1.38 (0.67%)
BAC  52.55
+0.03 (0.06%)
GOOG  306.02
-3.35 (-1.08%)
META  639.77
-10.04 (-1.55%)
MSFT  401.32
-0.52 (-0.13%)
NVDA  182.81
-4.13 (-2.21%)
ORCL  160.14
+3.66 (2.34%)
TSLA  417.44
+0.37 (0.09%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.